10-K: Option Care Health Reports FY2024 Results, Revenue Climbs 16.2%

Option Care Health's FY2024 revenue increased by 16.2%, driven by organic growth in both acute and chronic therapies, though gross profit margin declined due to therapy mix and procurement dynamics.

Summary

• Option Care Health, Inc. reported its financial results for the fiscal year ended December 31, 2024.
• The company's net revenue increased by 16.2% to $4,998.2 million, compared to $4,302.3 million in 2023.
• This growth was primarily driven by organic expansion in the company's portfolio of therapies, with acute revenue growing in the high single digits and chronic revenue growing in the high teens.
• Cost of revenue increased by 20.0% to $3,985.2 million, driven by revenue growth, therapy mix, acute drug supply chain disruption, and the impact of temporary favorable therapy procurement dynamics in the prior year.
• Gross profit increased by 3.2% to $1,012.9 million, but the gross profit margin decreased from 22.8% to 20.3%.
• The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth and the comparable impact of certain temporary favorable procurement dynamics in the prior year.
• Selling, general, and administrative expenses increased by 3.8% to $630.3 million, but decreased as a percentage of revenue from 14.1% to 12.6%.
• Net income decreased by 20.7% to $211.8 million, primarily due to the $106.0 million termination fee received in 2023 related to the Amedisys merger agreement.
• The company's effective tax rate was 25.3% for 2024, compared to 25.5% in 2023.
• Cash and cash equivalents increased to $412.6 million from $343.8 million.
• The company had $395.9 million available under its revolving credit facilities as of December 31, 2024.
• In January 2025, the Board of Directors approved a new $500 million stock repurchase program.
• The company expects a negative impact on gross profit of approximately $60 million to $70 million in 2025 due to a manufacturer's intention to significantly reduce the spread at which the Company procures a certain therapy relative to drug reference prices beginning in early 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. Revenue growth is positive, but declining profit margins and a projected future impact from pricing changes temper the outlook. The stock repurchase program is a positive signal, but overall, the sentiment is neutral to slightly positive.

Positives

• Net revenue increased by 16.2% year-over-year, indicating strong organic growth.
• Selling, general, and administrative expenses decreased as a percentage of revenue, demonstrating improved efficiency.
• Cash and cash equivalents increased, providing financial flexibility.
• The company has a new $500 million stock repurchase program, which could enhance shareholder value.
• The company completed the acquisition of Intramed Plus, Inc. in January 2025, expanding its market presence.

Negatives

• Gross profit margin decreased from 22.8% to 20.3%, indicating increased costs relative to revenue.
• Net income decreased by 20.7%, primarily due to the non-recurrence of a one-time termination fee.
• A manufacturer's pricing change is expected to negatively impact gross profit by $60-70 million in 2025.

Risks

• The company faces potential negative impacts from changes in relationships with pharmaceutical suppliers, including changes in drug availability or pricing.
• A shortage of qualified registered nursing staff, pharmacists, and other professionals could adversely affect the company's ability to attract and retain qualified personnel and could increase operating costs.
• Federal actions and legislation may reduce reimbursement rates from governmental payers and adversely affect the company's results of operations.
• Delays in reimbursement may adversely affect the company's liquidity, cash flows, and results of operations.
• The company is subject to pricing pressures and other risks involved with Third-Party Payers.
• A cyber-attack, security breach, or the company's inability to effectively integrate, manage, and keep its information systems secure and operational could disrupt operations.

Future Outlook

The company expects a negative impact on gross profit of approximately $60 million to $70 million in 2025 due to a manufacturer's intention to significantly reduce the spread at which the Company procures a certain therapy relative to drug reference prices beginning in early 2025.

Industry Context

The company competes in the large and highly fragmented home and alternative site infusion market. The company believes that its reputation for providing quality services, the strength of its national presence and its ability to effectively market its services at national, regional and local levels places it in a strong position against existing and potential competitors.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• The document mentions competitors such as Optum Infusion Pharmacy, Coram CVS/specialty infusion services, Amerita Specialty Pharmacy, KabaFusion, Soleo Health, Vital Care, Accredo, CVS Caremark, Optum Rx, and Orsini, but does not provide a detailed comparison of financial performance or operational metrics.
• Without specific data, it is difficult to assess Option Care Health's performance relative to industry peers.

Related Party Transactions

• The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses.
• On February 28, 2023, we entered into a Share Repurchase Agreement (the Share Repurchase Agreement) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I.
• On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.

Stakeholder Impact

• Shareholders may benefit from the stock repurchase program.
• Employees may be affected by cost management initiatives.
• Customers (patients) should see continued service, with potential changes in therapy costs.
• Suppliers may be affected by changes in procurement strategies.
• Creditors should be aware of the company's debt levels and interest rate risk.

Next Steps

• The company will continue to focus on organic growth and managing costs.
• The company will monitor the impact of the manufacturer's pricing change on gross profit in 2025.
• The company will execute its new $500 million stock repurchase program.
• The company will integrate Intramed Plus, Inc. into its operations.

Key Dates